Showing results (171-180 of 196) with videos related to

Sort By:
Pageof 20
The Lancet. Gastroenterology & Hepatology|May 9, 2021
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort studyBehzad Hajarizadeh, Jason Grebely, Marianne Byrne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 19, 2022
Characteristics of Human Immunodeficiency Virus (HIV) Seroconversions in a Large Prospective Implementation Cohort Study of Oral HIV Preexposure Prophylaxis in Men Who Have Sex with Men (EPIC-NSW)Nila J Dharan, Fengyi Jin, Stefanie Vaccher, et al.
The International Journal on Drug Policy|June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE studyHåvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
Plos One|April 4, 2015
Patterns of hepatitis C virus RNA levels during acute infection: the InC3 studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
Journal of Virology|May 26, 2017
Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment InterruptionWen Shi Lee, Anne B Kristensen, Thomas A Rasmussen, et al.
The Journal of Infectious Diseases|March 14, 2018
Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care AssayFrancois M J Lamoury, Sahar Bajis, Behzad Hajarizadeh, et al.
The International Journal on Drug Policy|May 9, 2022
Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage studyHeather Valerio, Maryam Alavi, Anna Conway, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 27, 2014
Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) studyBehzad Hajarizadeh, Bart Grady, Kimberly Page, et al.
Drug and Alcohol Dependence|June 30, 2022
Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage StudyAlice Wheeler, Heather Valerio, Evan B Cunningham, et al.
The International Journal on Drug Policy|June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE studyJason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Pageof 20